Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study

European Respiratory Journal

Volumn 21, Issue 1, 2003, Pages 116-122

  Schramm, Barbara ^a   Ehlken, B ^a   Smala, A ^a   Quednau, K ^b   Berger, K ^a   Nowak, D ^c  

^a Medical Economics Research Group MERG   (Germany)

^b Novartis Pharma   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atopic asthma; Cost of illness; Direct costs; Indirect costs; Rhinitis; Severity of disease

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NEDOCROMIL; NEDOCROMIL SODIUM; THEOPHYLLINE;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; CHILD; CONTROLLED STUDY; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GERMANY; HEALTH CARE COST; HOUSEHOLD; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEASONAL VARIATION;

ADOLESCENT; ADULT; AGED; ASTHMA; CHILD; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DRUG COSTS; FEMALE; GERMANY; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX;

EID: 0037246873     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00019502     Document Type: Article

References (27)

1. von Mutius E. The rising trends in asthma and allergic disease. Clin Exp Allergy 1998; 28: Suppl. 5, 45-49.
2. de Weck A. Allergies, an increasing public health problem: causes and consequences. Allergy Immunol 2000; 32: 6-11.
3. Burney P, Chinn S, Jarvis D, Luczynska C, Lai E and on behalf of the European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996; 9: 687-695.
4. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalences of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 1225-1232.
5. Slavin RG. Sinopulmonary relationships. Am J Otolaryngol 1994; 15: 18-25.
6. Linna O, Kokkonen J, Lukin M. A 10-year prognosis for childhood allergic rhinitis. Acta Paediatr 1992; 81: 100-102.
7. Nowak D, Volmer T, Wettengel R. Asthma - eine Krankheitskostenanalyse. [Bronchial asthma - an economic evaluation]. Pneumologie 1996; 50: 364-371.
8. Weissflog D, Matthys H, Virchow JC Jr. Epidemiology and costs of bronchial asthma and chronic bronchitis in Germany. Dtsch Med Wochenschr 2001; 126: 803-808.
9. Wettengel R, Volmer T. Ökonomische Aspekte. In: Wettengel R, Volmer T, eds. Asthma - Medizinische und Ökonomische Bedeutung emer Volkskrankheit. [Asthma - Medical and economic relevance of a public disease]. Stuttgart, Norbert Rupp, 1994; pp. 35-68.
10. Schulenburg JM, Greiner W, Molitor S, Kielhorn A. Kosten der Asthmatherapie nach Schweregrad. Eine empirische Untersuchung. [Costs of asthma therapy according to level of severity]. Med Klin 1996; 91: 670-676.
11. Welsh PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987; 62: 125-134.
12. Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio, RM. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 1987; 316: 1506-1510.
13. Thefeld W, Bergmann K, Hermann-Kunz E. Wohnortgöβe und Gesundheit: Stadt-/Landunterschiede. [Place of domicile and health: Differences between urban and rural areas]. In: Bellach B-M, ed. Die Gesundheit der Deutschen. [Health in Germany]. Bd. 2, Heft 15, 1996; pp. 1-15.
14. National Heart Lung and Blood Institute. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. Publication no. 95-3659. Bethesda, National Institutes of Health, 1995.
15. Mundenbruch R. Einheitliche Bewertungsmaßstab (EBM): Bewertungsmaβstab für kassenärztliche Leistungen (BMÄ) und Ersatzkassen-Gebührenordnung (E-GO). [German tariff list for medical services (EBM). October 2000. Federal Association of Public Health Insurers (KBV)]. 31st edn. Germany, Zauner Verlag, 2000.
16. Rote Liste 2000. Arzneimittelverzeichnis für Deutschland (einschliesslich EU-Zulassungen und bestimmter Medizinprodukte. [Tariff list for drugs in Germany (including EU-admissions and special medical products)]. Frankfurt, Red List Service GmbH; 2000.
17. Anonymous. Zahlenbericht 1999/2000. Verband der Privaten Krankenversicherung. [Report 1999/2000. Association of private health insurance]. Köln, Verband der Privaten Krankenversicherung, 2000.
18. Ungar WJ, Peter CC and and the Pharmacy Medication Monitoring Program Advisory Board. Measuring productivity loss days in asthma patients. Health Econ 2000; 9: 37-46.
19. Federal Statistical Office. Statistisches Jahrbuch 2000 fü die Bundesrepublik Deutschland. [Statistical Yearbook 2000 for the Federal Republic of Germany]. Wiesbaden, Metzler-Poeschel, 2000.
20. Liebl A, Neiss A, Spannheimer A, et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2TM study. Exp Clin Endocrinol Diabetes 2002; 110: 10-16.
21. Palmer AJ, Brandt A, Gozzoli V, Weiss C, Stock H, Wenzel H. Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract 2000; 50: Suppl. 3, 47-56.
22. Serra-Batlles J, Plaza V, Morejón E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12: 1322-1326.
23. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19: 61-67.
24. Szucs TD, Anderhub H, Rutishauser M. The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J 1999; 13: 281-286.
25. Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and costs associated with an asthma attack. Thorax 2000; 55: 19-24.
26. Wettengel R, Berdel D, Hofmann D, et al. Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga. [Asthma therapy in children and adults. Recommendations of the German Respiratory League]. Med Klin 1998; 93: 639-650.
27. Sachverständigenrat für die konzertierte Aktion im Gesundheitswesen. Bedarfsgerechtigkeit und Wirtschaftlichkeit, Band III. Über- Unter- und Fehlversorgung. [Advisory Council for the Concerted Action in Healthcare. Appropriateness and efficiency, Volume III. Over-, under- and misuse]. Report 2000/2001. Baden Baden, Nomos Verlagsgesellschaft, 2002.